Iovance Biotherapeutics (IOVA) News Today

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) appears to be getting a modest lift from a batch of analyst estimate revisions that are mostly constructive for near-term profitability, even though some longer-dated forecasts were trimmed. The stock has also drawn attention from a Zacks comparison piece that highlighted Iovance’s commercial momentum and expanding Amtagvi pipeline as reasons it may be better positioned than peers.

• Positive Sentiment: Zacks Research raised its FY2026 earnings estimate for Iovance Biotherapeutics and also nudged up expectations for Q2 2026, Q1 2027, Q2 2027, and Q1 2028, suggesting improving near-term outlook and some progress toward narrowing losses.
• Positive Sentiment: A Zacks article argued that Iovance’s commercial momentum and expanding Amtagvi pipeline make it look better positioned than Agenus, which may support investor sentiment around the company’s growth story. Article Title
• Neutral Sentiment: Analysts still expect Iovance to post losses across the forecast period, including a consensus full-year loss estimate of about $0.63 per share, so the company remains a turnaround story rather than a profitable one.
• Negative Sentiment: Zacks Research lowered several longer-term estimates, including Q3 2026, Q4 2026, Q3 2027, Q4 2027, and FY2028, which may temper enthusiasm by implying a slower earnings recovery farther out.